Core Viewpoint - 康圣环球 (09960.HK) is scheduled to hold a board meeting on August 28, 2025, to review and approve the interim results for the six months ending June 30, 2025 [1] Group 1 - The board meeting will focus on the group's interim performance [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 董事會召開日期 康聖環球基因技術有限公司（「本公司」及其附屬公司「本集團」）董事會（「董事 會」）茲通告謹定於二零二五年八月二十八日（星期四）舉行董事會會議，藉以考慮 及通過本集團截至二零二五年六月三十日止六個月的綜合中期業績及其發佈，以 及處理其他事項。 承董事會命 康聖環球基因技術有限公司 主席 黃士昂 Kindstar Globalgene Technology, Inc. 康聖環球基因技術有限公司 香港，二零二五年八月十四日 （於開曼群島註冊成立的有限公司） 於本公告日期，董事會包括執行董事黃士昂醫生、涂贊兵先生及柴海節女士；非 執行董事黃瑞瑨先生、彭偉先生及黃璐女士；以及獨立非執行董事姚尚龍博士、 夏新平博士及顧華明先生。 （股份代號：9960） ...

本月底法定/註冊股本總額： USD 500,000 FF301 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,0 ...

Group 1 - The core viewpoint of the article highlights that Kangsheng Global (09960) has been recognized as the "Best Strategic Investment Institution in Medical Health" by Haoyue Capital, reflecting the company's achievements in strategic investments [1] - The "Medical Health Investment Excellence List" has become an important benchmark for assessing market value and brand influence in the medical health investment industry, focusing on the activity level, transaction volume, return performance, and post-investment empowerment of investment institutions [1] - Since its listing, Kangsheng Global has focused on specialized testing services, particularly in hematology, neurology, and solid tumors, reinforcing its leading position in the industry through continuous R&D investment and market expansion [1] Group 2 - In June 2024, Kangsheng Global acquired an 11.38% stake in Beijing Bofurui Gene Diagnostic Technology Co., enhancing its core testing technology's penetration and influence in the transplant market [2] - In September 2024, the company acquired 100% of Guangzhou Benchmark Medical, quickly entering the major solid tumor testing market, particularly for lung and gastric cancers, and expanding its early screening and diagnosis product pipeline [2] - In June 2025, Kangsheng Global established a joint venture with Biostate AI to leverage data and AI technology for early screening and diagnosis, promoting development in the precision medicine sector [2] Group 3 - The Chinese medical health industry is experiencing a structural recovery in 2025, with Kangsheng Global committed to driving innovation and the synergistic development of technology and services [3] - The company aims to actively seek potential market targets, utilizing valuation gaps to integrate complementary technology firms, thereby enhancing its risk resilience and growth potential [3] - Through mergers and acquisitions, along with its own products and services, Kangsheng Global is forming a balanced strategy to navigate challenges and continue progressing [3]

Group 1 - The core viewpoint of the articles highlights the recognition of 康圣环球 (Kangsheng Global) as the "Best Strategic Investment Institution in Healthcare" by 浩悦资本 (Haoyue Capital), reflecting the company's achievements in strategic investments [1] - The "Healthcare Investment Excellence List" by Haoyue Capital has become an important benchmark for assessing market value and brand influence in the healthcare investment industry, focusing on the activity level, transaction volume, return performance, and post-investment empowerment of investment institutions [1] - 康圣环球 has maintained a leading position in specialized testing by focusing on hematology, neurology, and solid tumors, continuously expanding its business boundaries through R&D investment and market expansion to meet growing clinical demands [1] Group 2 - In June 2024, 康圣环球 acquired an 11.38% stake in Beijing Bofurui Gene Diagnostic Technology Co., enhancing its core testing technology's penetration and influence in the transplant market [2] - In September 2024, 康圣环球 acquired 100% of Guangzhou Benchmark Medical, quickly entering the major solid tumor testing market, particularly for lung and gastric cancers, and expanding its IVD product pipeline [2] - In June 2025, 康圣环球 established a joint venture with Biostate AI to leverage data and AI technology for early screening and diagnosis, promoting development in precision medicine [2] Group 3 - The Chinese healthcare industry is experiencing a structural recovery in 2025, with 康圣环球 focusing on innovation to drive the synergy between technology and services [3] - The company aims to identify potential market targets and utilize valuation gaps to integrate complementary technology firms, enhancing its risk resilience and growth potential [3] - 康圣环球 plans to adopt a dual-track approach through mergers and its own products and services, maintaining a balanced strategy in the face of challenges [3]

Core Viewpoint - The third-party medical testing industry in China has experienced significant growth, particularly during the pandemic, with a market size reaching 630.5 billion yuan in 2022, but is expected to return to pre-pandemic levels in 2023 and stabilize around 388.8 billion yuan in 2024 [1][6]. Group 1: Industry Definition and Business Model - Medical testing is a discipline that utilizes modern physical and chemical methods for clinical diagnosis and treatment [2]. - Independent clinical laboratories (ICLs), also known as third-party medical laboratories, operate independently of hospitals and are licensed by health authorities to provide clinical testing and pathology services [2]. Group 2: Current Development Status - The ICL industry in China began in the 1980s and has become an essential part of the healthcare system due to increasing demand and favorable policies [4]. - The number of ICLs has grown from fewer than 70 in 2009 to an estimated 2,800 by 2024, with projections of reaching 2,845 by 2025 [4]. Group 3: Market Size and Growth Projections - The market size for third-party medical testing services in China was 630.5 billion yuan in 2022, with a significant drop expected in 2023 as pandemic testing demands decrease [6]. - The projected market size for 2024 is 388.8 billion yuan, with special testing accounting for 189.3 billion yuan and general testing for 199.5 billion yuan [6]. - By 2025, the market is expected to grow to approximately 444.9 billion yuan, with special testing at 218.1 billion yuan and general testing at 226.8 billion yuan [6]. Group 4: Industry Chain Structure - The third-party medical testing industry relies on specialized medical services, acting as a substitute for traditional hospital testing departments [8]. - The upstream of the industry includes suppliers of medical devices and testing reagents, while the downstream consists of various healthcare institutions that increasingly outsource testing services [8]. Group 5: Competitive Landscape - The market is characterized by a concentration of major players, with KingMed and Dian Diagnostics holding a combined market share of 36.16% [15]. - KingMed leads the market with a 17.04% share, providing services to over 20,000 medical institutions across 31 provinces and regions [15]. - Smaller third-party testing institutions face challenges due to limited scale and capabilities, leading to market exit pressures since 2015 [15]. Group 6: Financial Performance of Key Players - In 2024, KingMed reported revenues of 6.627 billion yuan, Dian Diagnostics 4.520 billion yuan, and Aidi Kang 2.914 billion yuan, among others [18]. Group 7: Development Trends - The third-party medical testing sector is becoming increasingly important, with regulatory changes posing new challenges [20]. - The industry is expected to focus on technological upgrades and strategic partnerships to enhance profitability and service quality [20]. - Automation, platformization, and intelligence are emerging as key trends in the development of third-party medical laboratories [20].

Core Insights - Kindstar Global and Biostate AI have officially signed an agreement to establish a joint venture aimed at advancing AI-driven precision medical solutions globally, particularly in China [1] - The collaboration will leverage Kindstar Global's extensive clinical testing network covering over 3,000 hospitals in China and Biostate AI's innovative RNA sequencing and AI technology [2][3] - The joint venture will focus on developing innovative diagnostic solutions tailored to the clinical needs in China, enhancing Kindstar Global's leadership in the precision medicine sector [3][4] Company Overview - Kindstar Global is recognized as a leading clinical testing service provider in China, with a robust network that supports the integration of data, diagnostics, and AI [2] - Biostate AI aims to create an AI system that truly understands human biology, enabling personalized medical treatments based on real-time data analysis [2] - The joint venture will initially target five prevalent specialty diseases: autoimmune diseases, oral cancer, diabetes, lymphoma, and post-organ transplant management [4] Strategic Goals - The partnership is seen as a significant milestone in both companies' strategic development, combining Biostate AI's innovative capabilities in RNA sequencing and AI algorithms with Kindstar Global's market expertise [4] - The joint venture will focus on optimizing and validating Biostate AI's RNA sequencing technology for the Chinese population's disease spectrum [4] - The collaboration aims to create a leading global precision medical platform, providing efficient and accurate diagnostic tools for healthcare professionals and patients [4]

Core Insights - The partnership between 康圣环球基因技术有限公司 and Biostate AI aims to leverage their combined strengths in data resources, AI algorithms, and biotechnology to accelerate the clinical application of artificial intelligence in precision medicine and commercial promotion [1][4]. Group 1: Technological Advancements - 康圣环球 will provide its accumulated RNA sequencing (RNAseq) data resources to support AI model training for the joint venture [1]. - Biostate AI's Total RNA sequencing service utilizes the innovative Barcoded Integrated Reverse Transcription (BIRT) technology, allowing for high-throughput analysis of over 300,000 non-coding RNA types, significantly enhancing transcriptome information [1]. - The BIRT technology reduces RNA sequencing costs by nearly 5 times and improves data quality, enabling research teams to process 2-3 times more samples within the same budget [1][3]. Group 2: Market Potential - The global AI market in genomics is rapidly growing, with an estimated market size of approximately $498 million in 2022 and a projected compound annual growth rate (CAGR) of 46% from 2023 to 2030 [4]. - The partnership is positioned to capitalize on the increasing demand for personalized medicine and the growing investment in research, making data quality and scarcity key competitive indicators [4]. Group 3: Clinical Applications - The collaboration has already begun working on RNAseq datasets from leukemia patients, achieving results comparable to flow cytometry and pathology techniques [5]. - By lowering the barriers to RNA sequencing, Biostate AI's technology is expected to advance the early warning time for major diseases like cancer by 6-12 months and increase the success rate of drug clinical trials by approximately 30% [6]. Group 4: Strategic Goals - The joint venture will initially focus on introducing Biostate AI's RNA sequencing technology and AI analysis platform to the Chinese market, optimizing and validating it for the disease spectrum characteristics of the Chinese population [6]. - The partnership plans to explore applications in tumor liquid biopsy, drug genomics, and rare disease diagnosis, collaborating with top medical institutions and research institutes in China [7]. Group 5: Data Security and Compliance - Biostate AI emphasizes a "de-identified data cohort" and "federated learning" strategy to ensure data privacy while retaining scientific value, complying with global and Chinese regulations [7]. - The leadership of the joint venture includes 康圣环球's CEO as chairman and Biostate AI's co-founder as chief AI officer, indicating a strong commitment to integrating medical and technological advancements [7].

Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching $150 million for the fiscal year 2024[2]. - Revenue for 2024 was RMB 927,568 thousand, a decrease of 4.1% compared to RMB 967,260 thousand in 2023[17]. - The company reported a loss before tax of RMB (56,190) thousand in 2024, compared to a profit of RMB 43,322 thousand in 2023[17]. - The company reported a net loss of RMB 60.681 million for 2024, a significant decline compared to a profit of RMB 36.447 million in 2023, reflecting a 266.5% year-over-year change[44]. - The gross profit decreased by 2.6% year-over-year, amounting to RMB 439.563 million in 2024, down from RMB 451.129 million in 2023[44]. - The overall operating performance increased to RMB 157.4 million, up 9.8% from RMB 143.3 million in 2023, attributed to improved internal management efficiency and cost control measures[58]. - Other income decreased from RMB 138.1 million in 2023 to RMB 120.5 million, primarily due to the absence of a government subsidy received in the previous year[59]. - Cash flow from operations increased by 50%, totaling $30 million, providing a strong liquidity position for future investments[2]. - Cash flow from operating activities was a net outflow of RMB 44.1 million, mainly due to extended remittance periods and reduced government subsidies[70]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2026[2]. - The company provided guidance for 2025, projecting a revenue growth of 20% to $180 million[2]. - The company aims to expand its business footprint through strategic acquisitions and resource integration, enhancing risk resilience and market competitiveness[20]. - The company is focusing on market expansion, targeting a 20% increase in market share within the next two years[118]. - The company plans to deepen its strategic positioning in "precision diagnosis driving clinical value" through strategic investments and acquisitions in 2025[40]. Product Development and Innovation - New product launches contributed to 30% of total revenue, with the latest product generating $45 million in sales[2]. - The company has launched an intelligent tumor report analysis system, significantly improving report interpretation efficiency[28]. - The company has initiated the development of immune diagnostic reagent kits in collaboration with partners, aiming for clinical registration in the second half of 2024[30]. - The company plans to invest $50 million in research and development to enhance its technological capabilities[118]. - The company achieved a significant increase in sales of targeted pathogen sequencing projects, with an annual growth rate exceeding 40%[28]. Research and Development - Investment in R&D increased by 40%, amounting to $20 million, focusing on innovative technologies[2]. - The company’s R&D department added 264 new testing projects, including 130 related to molecular biology testing technology[31]. - The company developed 74 types of fusion gene screening and reverse transcriptase reagent kits, achieving a completion rate of 91.4% for 35 NGS reagent kits[34]. - The company plans to introduce two additional PacBio Revio third-generation sequencing systems in 2025, enhancing its sequencing capacity and throughput[52]. Corporate Governance - The board of directors is committed to maintaining high standards of corporate governance and transparency[118]. - The company has adopted the principles and code provisions of the corporate governance code as the basis for its governance practices[122]. - The company has established a risk management and internal control system that is deemed effective and adequate as of the annual review conducted on March 28, 2025[182]. - The audit committee consists of two independent non-executive directors and one non-executive director, ensuring compliance with corporate governance standards[148]. - The company has implemented a shareholder communication policy to address shareholder concerns effectively and regularly reviews its effectiveness[195]. Human Resources and Diversity - The company provides competitive compensation packages to retain employees, including salaries, discretionary bonuses, and benefits plans[83]. - The senior management team has a gender diversity ratio of 33.3%, with 1 female and 2 male executives[158]. - Overall employee gender ratio shows 66.9% female (2,006 employees) and 33.1% male (1,005 employees)[158]. - The company aims to promote gender diversity in senior management recruitment to develop potential female successors for the board[155]. Financial Management - The company has a commitment to maintaining effective communication with shareholders to enhance investor relations and understanding of its business performance and strategies[194]. - The company has a written guideline for employees regarding securities trading to prevent insider trading violations[124]. - The company has established various communication channels to engage with shareholders and ensure their rights are protected during significant decisions[189]. - The company aims to provide satisfactory and sustainable returns to shareholders while ensuring high-quality products and services for customers[120].

Group 1 - The company reported a revenue of RMB 928 million for the year ending December 31, 2024, with a gross profit of RMB 440 million and a net loss of RMB 60.68 million, resulting in a loss per share of 5.77 cents [1] - The decline in gross profit was attributed to a revenue decrease of RMB 39.7 million and increased fixed asset investments, including the establishment of new laboratories in Shanghai and Guangzhou [1] - Despite the decline in gross profit, the gross margin improved compared to 2023 due to product structure enhancement, cost control, and efficiency improvements [1] Group 2 - In 2024, China's regulatory scrutiny of the healthcare industry intensified, leading to a critical period of adjustment and standardization for the third-party medical testing industry, posing challenges to operational strategies, business models, and compliance management [2] - The demand for precision medicine and specialized testing is increasing due to economic development and heightened public health awareness, providing opportunities for companies in the sector [2] - The company aims to leverage its deep expertise in specialized testing to expand its focus areas through multiple technology platforms and testing projects, while also pursuing strategic acquisitions for business expansion and resource optimization [2]